Mind Medicine Inc. (NASDAQ: MNMD) is advancing its lead candidate, MM120, a pharmaceutically optimized form of lysergic acid diethylamide (LSD), through pivotal Phase 3 clinical…
Mind Medicine Inc. (NASDAQ: MNMD) is advancing its lead candidate, MM120, a pharmaceutically optimized form of lysergic acid diethylamide (LSD), through pivotal Phase 3 clinical…